期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 180, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.addr.2021.114043
关键词
Focused ultrasound; Micro-bubbles; Brain cancer; Blood brain barrier; Blood tumor barrier; Ultrasound Immunomodulation; Drug delivery
资金
- NIH (National Institutes of Health) [R37CA239039]
- NSF (National Science Foundation) [1933158]
- NIH [R21NS113016, R21NS118232]
- Focused Ultrasound Foundation [20010533]
Brain tumors located in the central nervous system (CNS) present a unique challenge due to limited drug access to the brain tumor microenvironment (TME). Recent advancements in microbubble ultrasound contrast agents and ultrasound energy have shown promise in enhancing drug delivery to brain tumors. This technology has the potential to improve the effectiveness of both traditional chemotherapy and novel immunotherapeutic agents. Early clinical studies have demonstrated safety, and ongoing Phase I/II trials are testing the preclinical findings.
Brain tumors are particularly challenging malignancies, due to their location in a structurally and functionally distinct part of the human body - the central nervous system (CNS). The CNS is separated and protected by a unique system of brain and blood vessel cells which together prevent most bloodborne therapeutics from entering the brain tumor microenvironment (TME). Recently, great strides have been made through microbubble (MB) ultrasound contrast agents in conjunction with ultrasound energy to locally increase the permeability of brain vessels and modulate the brain TME. As we elaborate in this review, this physical method can effectively deliver a wide range of anticancer agents, including chemotherapeutics, antibodies, and nanoparticle drug conjugates across a range of preclinical brain tumors, including high grade glioma (glioblastoma), diffuse intrinsic pontine gliomas, and brain metastasis. Moreover, recent evidence suggests that this technology can promote the effective delivery of novel immunotherapeutic agents, including immune check-point inhibitors and chimeric antigen receptor T cells, among others. With early clinical studies demonstrating safety, and several Phase I/II trials testing the preclinical findings underway, this technology is making firm steps towards shaping the future treatments of primary and metastatic brain cancer. By elaborating on its key components, including ultrasound systems and MB technology, along with methods for closed-loop spatial and temporal control of MB activity, we highlight how this technology can be tuned to enable new, personalized treatment strategies for primary brain malignancies and brain metastases.(c) 2021 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据